ICU antibiotic dosing under the microscope: new study targets dialysis clearance

NCT ID NCT07167524

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how the antibiotics piperacillin and tazobactam are cleared from the body by continuous kidney replacement therapy in intensive care patients with severe infections. Researchers will measure drug levels in 24 adults to better understand dosing needs. The goal is to improve treatment effectiveness and reduce risks like underdosing or toxicity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: piperacillin and tazobactam (antibiotics)
What this could lead to: If successful, this could help doctors determine the right antibiotic doses for ICU patients on kidney dialysis, potentially improving treatment and reducing side effects.
What could go wrong: This is a small, early observational study with only 24 participants. It does not test a new treatment, so it may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS SEVERE BACTERIAL INFECTIONS

Contacts and locations

Locations

University Rouen Hospital

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.